1015609-35-4

Basic information

• Product Name: 1H-PYRROLO[3,2-B]PYRIDIN-6-OL
• Synonyms: 1H-PYRROLO[3,2-B]PYRIDIN-6-OL;6-Hydroxy-4-azaindole;(R)-2-aMino-3-(4-(aMinoMethyl)phenyl)propanoic acid
• CAS NO: 1015609-35-4
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134
• Mol File: 1015609-35-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 369.7 °C at 760 mmHg
• Flash Point: 177.4 °C
• Appearance: /
• Density: 1.434 g/cm³
• PKA: 5.93±0.40(Predicted)
• CAS DataBase Reference: 1H-PYRROLO[3,2-B]PYRIDIN-6-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRROLO[3,2-B]PYRIDIN-6-OL(1015609-35-4)
• EPA Substance Registry System: 1H-PYRROLO[3,2-B]PYRIDIN-6-OL(1015609-35-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1015609-35-4(Hazardous Substances Data)

Usage

General Description

1H-Pyrrolo[3,2-b]pyridin-6-ol, also known as 6-hydroxy-1H-pyrrolo[3,2-b]pyridine, is a chemical compound with the molecular formula C8H6N2O. It is a heterocyclic compound containing a pyrrole ring fused to a pyridine ring with a hydroxyl group attached at the 6-position. 1H-Pyrrolo[3,2-b]pyridin-6-ol has potential biological activity and is being studied for its potential use in pharmaceuticals and medicinal applications. It has been reported to have antifungal and antibacterial properties, and it may also have potential as an antitumor agent. Additionally, 1H-Pyrrolo[3,2-b]pyridin-6-ol may have uses in organic synthesis and materials science due to its unique structure and properties.

Upstream product

• 24509-73-7 1-(1H-pyrrolo[3,2-b]pyridin-1-yl)ethanone 

Downstream Products

• 1175013-57-6 4-[2-(2,6-dimethyl-phenoxy)-6-hydroxy-1-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Core Replacements in a Potent Series of VEGFR-2 Inhibitors and Their Impact on Potency, Solubility, and hERG

Anti-VEGF therapy has been a clinically validated treatment of age-related macular degeneration (AMD). We have recently reported the discovery of indole based oral VEGFR-2 inhibitors that provide sustained ocular retention and efficacy in models of wet-AMD. We disclose herein the synthesis and the biological evaluation of a series of novel core replacements as an expansion of the reported indole based VEGFR-2 inhibitor series. Addition of heteroatoms to the existing core and/or rearranging the heteroatoms around the 6-5 bicyclic ring structure produced a series of compounds that generally retained good on-target potency and an improved solubility profile. The hERG affinity was proven not be dependent on the change in lipophilicity through alteration of the core structure. A serendipitous discovery led to the identification of a new indole-pyrimidine connectivity: from 5-hydroxy to 6-hydroxyindole with potentially vast implication on the in vitro/in vivo properties of this class of compounds.